Key result
Cancer patients with acute coronary syndrome face high thrombotic and bleeding risks, requiring individualized, multidisciplinary management strategies for antiplatelet therapy and revascularization.
Why the study?
Cancer patients have an elevated prevalence of coronary artery disease and cardiovascular risk factors associated with high mortality, while oncological therapies and prothrombotic states complicate treatment decisions.
This review highlights the complex interplay between cancer, cardiotoxic therapies, and acute coronary syndrome, emphasizing the need for individualized, multidisciplinary management to balance ischemic and bleeding risks.
Requires individualized ACS management in cancer patients; leaves open optimal strategies pending higher-level evidence.
Cancer and cardiovascular disease are the leading causes of mortality in the world. The prevalence of cardiovascular risk factors and coronary artery disease in cancer patients is elevated, and it is associated with high mortality. Several mechanisms, such as the proinflammatory and procoagulant states present in cancer patients, may contribute to these scenarios. Oncological therapy can predispose patients to acute thrombosis, accelerated atherosclerosis and coronary spasm. Treatment decisions must be individualized and based on the cancer history and balancing bleeding and thrombosis risks.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2021) conducted a review in Acute Coronary Syndrome in Cancer Patients. Management of Acute Coronary Syndrome was evaluated. Cancer patients with acute coronary syndrome face high thrombotic and bleeding risks, requiring individualized, multidisciplinary management strategies for antiplatelet therapy and revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: